Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

1 evidence topic · 1 source

Central foveal thickness as a pharmacodynamic marker

“Increased retinal thickness (e.g., central foveal thickness (CFT)) and leakage of blood and fluid from choroidal neovascularization is associated with nAMD. CFT is known to be a reproducible, early indication of pharmacodynamic response to anti-VEGF treatments.” (opens the prescribing information at this quote)

“Changes in CFT were assessed using optical coherence tomography in NORSE TWO and NORSE EIGHT [see Clinical Studies (14)]. Increasingly greater reductions in CFT were observed at Weeks 4, 8, and 12 across both treatment arms.” (opens the prescribing information at this quote)

“Anatomic data were not used to influence LYTENAVA treatment decisions.” (opens the prescribing information at this quote)